A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)

Inclusion Criteria:

* Age 18 years or above at the time of signing the informed consent form.
* Histologically proven diagnosis of stage I-III invasive breast cancer.
* Currently taking prescribed dose of an aromatase inhibitor (e.g., anastrazole, letrozole, exemestane) for at least 60 days with a plan to continue for at least 4 weeks after time of consent.
* Initiated AI therapy must have been within 48 months at time of consent.
* Experiencing AIMSS in hands and/or wrists for at least 4 weeks prior to time of consent.
* Patients must have reported a score of 4 or higher on at least one of the four M-SACRAH questions regarding pain and stiffness in hands and/or wrists over the past 7 days. Patients experiencing AIMSS symptoms in other joints are eligible, but must have pain in hands and/or wrists.
* Must be willing and able to comply with study visits and procedures.
* Must be willing to be registered in the Minnesota Medical Cannabis Program (MMCP).
* Must meet qualifications for the Minnesota Medical Cannabis

Program (MMCP). This includes:

1. Must have a qualifying condition, as per MMCP requirements, that is certified by a Health Care Practitioner.
2. Must be a Minnesota resident.

Exclusion Criteria:

* The patient is currently using or has used cannabinoids within 4 weeks of time of consent.
* Active skin lesions on hands/wrists that the investigator feels could impair absorption of cannabinoid cream or lead to increased toxicity (e.g., psoriasis, cellulitis, cutaneous lupus erythematosus, hand-foot syndrome).
* Plan to start or increase doses of other analgesics aimed at improving AIMSS symptoms (e.g., duloxetine, non-steroidal anti- inflammatories, acetaminophen, opioids). Of note, patients are eligible if they have remained on stable doses of AIMSS related medications for 4 weeks prior to time of consent and do not plan to escalate the dose.
* Current or planned initiation of acupuncture to arms, wrists or hands within study period.
* Any known or suspected hypersensitivity to topical cannabinoids.
* Any condition that the investigator believes would interfere with the ability to provide informed consent, comply with the study protocol, or would put the subject at undue risk.